Phenotypic Changes of Trichinella Spiralis Treated By Commiphora Molmol,Lepidium Sativum, and Albendazole: in Vitro Study.

Trichinellosis is a nematode-causing disease distinguished by its continuous transmission in the carnivores and omnivores. Despite effective eradication of the enteral forms, conventional drugs fail to eliminate the migrating and muscle ones. Over the past years, researchers intensified the work on herbal medicines as alternatives or aids to albendazole, the reference drug. This research hypothesizes that the therapeutic agent absorption route could be an evidence-based carrier molecule or auxiliary drug to albendazole. Accordingly, this in vitro study was designed to investigate mainly the phenotypic changes induced by a mono-treatment of albendazole, Lipidium sativum (garden cress), and Commiphora molmol (myrrh). Incredibly, no data were reported on the morphological alterations of T. spiralis larvae treated by any of these drugs. The experimental design tested various concentrations (25, 50, 100, and 200 µg/ml) of each herbal medicine for the lethal effects on the parasite forms for a day (1, 12, and 24h). The data showed that the highest significant mortality rate of the parasite forms was in favor of the concentration 200 µg/ml of both plant extracts in a time-dependent manner. Therefore, albendazole at 200 µg/ml dose was tested in parallel, and all experimental groups were compared to non-treated muscle larvae and worms. Albendazole-treated worms accounted for the least significant (p<0.001) survival rate (2 %), followed by myrrh (5 %), and the adverse was valid for the survival rate of the muscle larvae at that time. None of the larvae/worms was alive after 24 hours of incubation with the 200µg/ml of either treatment. The scanning electron microscope investigation of the experimental groups provided a shred of evidence for different routes of taking up the candidate drugs by the parasite. In conclusion, the results of the previous work in vivo and current in vitro study recommend myrrh over garden cress as a complementary agent of albendazole.

Antioxidant and schistosomicidal effect of Allium sativum and Allium cepa against Schistosoma mansoni different stages.

OBJECTIVE: The schistosomicidal properties of garlic (Allium sativum) and onion (Allium cepa) powder were tested in vitro against Schistosoma mansoni miracidia, schistosomula, cercaria and adult worms. Results indicate their strong biocidal effects against all stages of the parasite and also show scavenging inhibitory effect on 2,2-diphenyl-1-picrylhydrazyl (DPPH) and nitric oxide (NO). MATERIALS AND METHODS: In the present work, the in vivo effects of A. sativum and A. cepa on lipid peroxide and some antioxidant enzymes; thioredoxin reductase (TrxR), sorbitol dehydrogenase (SDH), superoxide dismutase (SOD), catalase (CAT) and glutathione reductase (GR) (as they have a crucial role in host protection against invading parasite) were also studied. RESULTS: The data demonstrate that, there was a significant inhibition in SOD, CAT, GR, TrxR and SDH in infected liver while, significant elevation was detected in lipid peroxide as compared to the normal control. The current resultS clearly revealed that, the used both edible plants enhance the host antioxidant system indicated by lowering in lipid peroxide and stimulation of SOD, CAT, GR, TrxR and SDH enzyme levels. CONCLUSIONS: Enhancement of such enzymes using A. sativum and A. cepa could in turn render the parasite vulnerable to damage by the host and may play a role in the antischistosomal potency of the used food ingredients.

[Immunomodulating therapy in chronic polyarthritis with thymopentin. A multicenter placebo-controlled study of 119 patients]. / Immunmodulierende Therapie der chronischen Polyarthritis mit Thymopentin. Eine multizentrische placebokontrollierte Studie an 119 Patienten.

In a multicenter, placebo-controlled and randomized double-blind trial 119 patients with rheumatoid arthritis were treated with thymopentin, an immunoregulating drug. The data of 107 patients were complete enough to be evaluated: 51 were given intravenous injections over ten minutes of 50 mg thymopentin three times weekly, 56 were similarly treated with a placebo solution. Significant improvement of five among nine clinical criteria were obtained with thymopentin after the third week of treatment. The response rate (improvement of a clinical parameter by at least 40%) was significantly greater for all clinical parameters in the thymopentin group. Regression to a functionally more favourable class (Steinbrocker's classification) occurred in seven thymopentin-treated, but in none of the placebo-treated patients. The improvement gradually subsided over four weeks after the end of treatment. There were no changes during the trial with respect to immunological, biochemical or haematological findings. Except for one systemic allergic reaction there were no side effects.

[Treatment of primary chronic polyarthritis with ranoroc (author's transl)]. / Zur Behandlung der primär chronischen Polyarthritis mit Ranoroc.

In the framework of a clinical study the butazone derivative Ranoroc was tested for efficacy and tolerance in 50 patients with primary chronic polyarthritis. The success rates both in previously treated and untreated patients were approximately equal, i. e. 92%. In the previously treated group, a superior effect of Ranoroc as compared with the earlier treatment was stated by the patients in 57% and by the physician in about 36% of the cases. The tolerance was very good. Nausea and heartburn occurred in 3 cases only and were controlled by reducing the dosage. Discontinuation of the trial was required in two cases on account of skin allergies. The continuously monitored laboratory parameters gave no evidence whatsoever of a negative influence, so that even a longterm treatment with Ranoroc seems possible.